Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from Adial Pharmaceuticals ( (ADIL) ) is now available.
Adial Pharmaceuticals has entered into a new Purchase Agreement with Alumni Capital LP, allowing the company to sell up to $5 million of newly issued shares, with the potential to increase to $10 million, at its discretion. This agreement provides Adial Pharmaceuticals with strategic flexibility in managing capital and funding operations, potentially impacting its market positioning by enabling investments in strategic opportunities, expanding staffing and capabilities, and supporting general corporate purposes.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. is a company involved in the pharmaceuticals industry, focusing on the development of therapeutic products. The company’s market focus is primarily on addressing unmet medical needs and developing treatment options for various health conditions.
YTD Price Performance: -39.25%
Average Trading Volume: 173,035
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.24M
Find detailed analytics on ADIL stock on TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
